Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Yingxia Liu, Yang Yang, Cong Zhang, Fengming Huang, Fuxiang Wang, Jing Yuan, Zhaoqin Wang, Jinxiu Li, Jianming Li, Cheng Feng, Zheng Zhang, Lifei Wang, Ling Peng, Li Chen, Yuhao Qin, Dandan Zhao, Shuguang Tan, Lu Yin, Jun Xu, Congzhao Zhou, Chengyu Jiang, Lei Liu, Yingxia Liu, Yang Yang, Cong Zhang, Fengming Huang, Fuxiang Wang, Jing Yuan, Zhaoqin Wang, Jinxiu Li, Jianming Li, Cheng Feng, Zheng Zhang, Lifei Wang, Ling Peng, Li Chen, Yuhao Qin, Dandan Zhao, Shuguang Tan, Lu Yin, Jun Xu, Congzhao Zhou, Chengyu Jiang, Lei Liu

Abstract

The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries. Here we report the epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China. All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS). The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count. The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity. ALB, LYM, LYM (%), LDH, NEU (%), and CRP were highly correlated to the acute lung injury. Age, viral load, lung injury score, and blood biochemistry indexes, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%), may be predictors of disease severity. Moreover, the Angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury. Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection.

Keywords: 2019-nCoV; ARDS; Angiotensin II.

Conflict of interest statement

Compliance and ethics The author(s) declare that they have no conflict of interest.

References

    1. Bi Y, Tan S, Yang Y, Wong G, Zhao M, Zhang Q, Wang Q, Zhao X, Li L, Yuan J, et al. Clinical and immunological characteristics of human infections with H5N6 avian influenza virus. Clin Infect Dis. 2019;68:1100–1109. doi: 10.1093/cid/ciy681.
    1. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, Xing F, Liu J, Yip CCY, Poon RWS, et al. Lancet. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.
    1. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828. doi: 10.1038/nature00786.
    1. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz M P, Prescott MF, Shi VC, Rouleau JL, Swedberg K, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC-Heart Failure. 2018;6:489–498. doi: 10.1016/j.jchf.2018.02.004.
    1. Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98:1627–1738. doi: 10.1152/physrev.00038.2017.
    1. Froch H, Nelges C, Tr T, Schwenger V, Cebola R, Schnorbach J, Goode KM, Kazmi S, Katus HA, Cleland JGF, et al. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Am Heart J. 2016;178:28–36. doi: 10.1016/j.ahj.2016.03.024.
    1. Guo J, Huang F, Liu J, Chen Y, Wang W, Cao B, Zou Z, Liu S, Pan J, Bao C, et al. The serum profile of hypercytokinemia factors identified in H7N9-infected patients can predict fatal outcomes. Sci Rep. 2015;5:10942. doi: 10.1038/srep10942.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Lancet. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
    1. Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, Li H, Wang W, Sheng M, Liu S, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014;5:3595. doi: 10.1038/ncomms4595.
    1. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;11:112–116. doi: 10.1038/nature03712.
    1. Jiang Y, Xu J, Zhou C, Wu Z, Zhong S, Liu J, Luo W, Chen T, Qin Q, Deng P. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005;171:850–857. doi: 10.1164/rccm.200407-857OC.
    1. Ko JH, Park GE, Lee JY, Lee JY, Cho SY, Ha YE, Kang CI, Kang JM, Kim YJ, Huh HJ, et al. Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infection. 2016;73:468–475. doi: 10.1016/j.jinf.2016.08.005.
    1. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879. doi: 10.1038/nm1267.
    1. Leem AY, Park B, Kim YS, Jung JY, Won S. Incidence and risk of chronic obstructive pulmonary disease in a Korean community-based cohort. Int J Chron Obstruct Pulmon Dis. 2018;13:509. doi: 10.2147/COPD.S148618.
    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung K SM, Lau EHY, Wong JY, et al. N Engl J Med. 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.
    1. Lin YC, Lin JW, Wu MS, Chen KC, Peng CC, Kang YN. Effects of calcium channel blockers comparing to angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. PLoS ONE. 2017;12:e0188975. doi: 10.1371/journal.pone.0188975.
    1. Liu CL, Lu YT, Peng MJ, Chen PJ, Lin RL, Wu CL, Kuo H T. Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever. Chest. 2004;126:509–517. doi: 10.1378/chest.126.2.509.
    1. Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, Good C, Restrepo MI, Downs JR, Frei CR, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumoniarelated outcomes. Clin Infect Dis. 2012;55:1466–1473. doi: 10.1093/cid/cis733.
    1. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720–723. doi: 10.1164/ajrccm/138.3.720.
    1. Niu P, Zhao G, Deng Y, Sun S, Wang W, Zhou Y, Tan W. A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice. Sci China Life Sci. 2018;61:1280–1282. doi: 10.1007/s11427-018-9343-8.
    1. Packer M, McMurray JJV. Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet. 2017;389:1831–1840. doi: 10.1016/S0140-6736(16)30969-2.
    1. Rai AK, Sanjukta S, Jeyaram K. Production of angiotensin I converting enzyme inhibitory (ACE-I) peptides during milk fermentation and their role in reducing hypertension. Crit Rev Food Sci Nutrit. 2017;57:2789–2800. doi: 10.1080/10408398.2015.1068736.
    1. Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, Gao GF G. A novel coronavirus genome identified in a cluster of pneumonia cases Wuhan, China 2019–2020. China CDC Weekly. 2020;2:61–62.
    1. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2267–2276. doi: 10.1056/NEJMoa1402686.
    1. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? Ann Surgery. 2003;237:319–334.
    1. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Sci China Life Sci. 2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.
    1. Yan YW, Liu Q, Li N, Du JC, Li X, Li C, Jin NY, Jiang CY. Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse. Sci China Life Sci. 2015;58:208–211. doi: 10.1007/s11427-015-4814-7.
    1. Yang Y, Wong G, Yang L, Tan S, Li J, Bai B, Xu Z, Li H, Xu W, Zhao X, et al. Comparison between human infections caused by highly and low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and virological findings. J Infection. 2019;78:241–248. doi: 10.1016/j.jinf.2019.01.005.
    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. N Engl J Med. 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019.
    1. Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594. doi: 10.1038/ncomms4594.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever